1 / 62

Renal Replacement Therapy

NEUROLOGICAL INJURY and RENAL REPLACEMENT THERAPY Lina C. Laxamana, FPCP, FPNA Neurocritical Care Unit October 8, 2010 NKTI Post Graduate Course. Renal Replacement Therapy. Indications: Severe hyperkalemia Fluid overload Refractory acidosis Uremic symptoms: Serositis Encephalopathy

carrington
Download Presentation

Renal Replacement Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NEUROLOGICAL INJURY and RENAL REPLACEMENT THERAPYLina C. Laxamana, FPCP, FPNANeurocritical Care UnitOctober 8, 2010NKTI Post Graduate Course

  2. Renal Replacement Therapy • Indications: • Severe hyperkalemia • Fluid overload • Refractory acidosis • Uremic symptoms: • Serositis • Encephalopathy • Bleeding • Objectives: • Remove excess volume • Remove solutes

  3. Renal Replacement Therapy

  4. Intensity of RRT and outcome in critically ill patients with ARF

  5. CASE • M.B., 56/M, married, from Isabela • Admitted due to sudden onset of R sided weakness and aphasia • ~11 hours PTA • Sudden onset of R sided weakness, with aphasia • Brought to a local hospital • Cranial CT requested

  6. Imaging ( 2 ½ hours)

  7. Imaging (2 ½ hours)

  8. Imaging (2 ½ hours)

  9. Imaging (2 ½ hours)

  10. Imaging (2 ½ hours) • Intracerebral hematoma with an estimated volume of 30cc in the L capsuloganglionic region. • With perilesional edema, mass effect and midline shift • No IVE, HCP

  11. Case • PMHx • With HPN, DM II, CAD • With ESRD requiring HD every 5th day through a L brachial AV fistula • Maintained on Plavix 75mg/tab, ½ tab daily • Denies allergies • PSHx • unremarkable

  12. Pertinent examination • E4V2M6 • Cranial nerves • Pupils 2mm EBRTL • R central facial palsy • Good gag • Tongue deviated to the R • Motors UE R 0/5 L 5/5 LE R 0/5 L 5/5

  13. Case • Pertinent labs • CBC 13.3/44.1/11.1/N92/249 • BT 4’ CT 5’ • PTT 35.1s PT 85% INR 1.06 • Na 127 K 5.89 • BUN 34 Crea 6.77 • Cranial CT repeated

  14. Imaging (10 ½ hours)

  15. Imaging (10 ½ hours)

  16. Imaging (10 ½ hours) • L capsuloganglionic acute intraparenchymal hematoma (42cc) • Surrounding edema • Compression of the ipsilateral ventricle and slight midline shift to the right

  17. Case • Admitted to NCCU • Started on Mannitol 60gms q4 • Neuro status quo: E4v2m6 • Pupils 2mm EBRTL • Slight headache • Started on HD

  18. Day 2 • Day 3 post ictus (830am) • E2v1m6, drowsier • BP 150/90 HR 90 O2sat 95% T 37.8C • Pupils 1mm, equal • Na 126 (124) K 5.89 (6.26) • Stat CT scan requested • NPO • Additional Mannitol 30gms bolus given

  19. Imaging (day 2)

  20. Imaging (day 2)

  21. Imaging (day 2)

  22. Imaging (day 2) • Interval evolution to beginning subacute stage • Without increase in volume • Interval progression of perilesional edema • Midline shift to the right has not significantly changed

  23. Case • Day 3 post ictus (915am) • Prepared for surgery • Repeat PT 138% INR 0.88 PTT 31.1s • Na and K correction • Mannitol continued at 60gms q4 • Hemodialysis • Clearances requested

  24. Case • Day 3 post ictus (1110am) • Elective intubation done (Anes) • Day 3 post ictus (515pm) • E2vtm5, more difficult to arouse • BP 166/100 HR 90 O2sat 100% • Pupils 2-3mm EBRTL • Awaiting repeat labs post HD

  25. Case • Day 3 post ictus (10pm) • K 4.35 • Scheduled for surgery at 4am • Day 4 post ictus (120am) • E2vtm5 • BP 160/90 HR 88 O2sat 98% • Pupils 2-3mm EBRTL

  26. Case • Day 4 post ictus (4am) • OR • Plan • L frontal craniotomy, endoscopic evacuation of hematoma with intraparenchymal ICP monitor probe insertion

  27. Case • Goals for treatment • Address the increased intracranial pressure from the hematoma • Evacuate the capsuloganglionic hemorrhage • Lessen the need for osmotic diuretics in an ESRD patient

  28. Surgery

  29. Surgery

  30. Surgery

  31. Surgery

  32. 4th day post-op

  33. Renal Replacement Therapy and the Neurocritical Care Patient

  34. Cerebral Blood Flow Lang & Chestnut, Neurosurg Clin N Am 1994;5(4):573-605

  35. Cerebral Blood Flow Bhardwaj A. Cerebral blood flow. In Suarez JI, Critical Care Neurology and Neurosurgery, Humana Press, 2004 with permission

  36. MAP = 2 (diastolic) + systolic 3 • CPP = MAP - ICP • CBF = Cerebral Perfusion Pressure Cerebral Vascular Resistance =P x  x r4 / 8 x L x  (Hagen-Poiseuille equation for movement of Newtonian fluids in large caliber vessels) • Autoregulation: MAP 60-150 mmHg

  37. IHD and ICP From: Davenport A. Hemod Internl 2008;12:307–312 with permission

  38. MAP and CAPD From: Davenport A. Hemod Internl 2008;12:307–312 with permission

  39. Effect of renal replacement on ICP From: Davenport A. Semin Dialysis, 2009;22:165–168 with permission

  40. Serum osmolality following renal replacement From: Davenport A. Semin Dialysis, 2009;22:165–168 with permission

  41. Modifications to standard hemodialysis prescription that may potentially reduce risk of further cerebral injury in patients with acute cererbal injury From: Davenport A. Hemod Internl 2008;12:307–312 with permission

More Related